,

Rev Esp Quimioter 2023; 36(4): 416-420

High macrolides and fluoroquinolones resistance rate in Mycoplasma genitalium in southern Tenerife

CRISTIAN MATEO LEÓN, DIEGO GARCÍA MARTÍNEZ DE ARTOLA, BERTA PINO-CALM

Published: 8 May 2023

http://www.doi.org/10.37201/req/014.2023

Introduction. Mycoplasma genitalium (MG) is a recognized sexually transmitted pathogen. Increasing resistance to main lines of treatment (macrolides and quinolones) justifies a genetic study of mutations to improve cure rates.
Material and methods. A total of 8,508 samples from April 2018 to July 2022 were processed using AllplexTM STI Essential Assay. In MG positive cases 23S rRNA V domain, gyrA and parC genes were studied. Mutations detected were checked to assess their clinical significance and medical records were reviewed to obtain demographic and treatment information.
Results. Resistance study was performed on 92 samples (65 men and 27 women). In relation to the genotypic study, 28 patients presented mutations to macrolides (30.43%). Most common was A2059G (18.48%). For quinolones, 5 patients (5.43%) had clinically relevant mutations in parC gene. Of note was a patient with G295 mutation in gyrA associated with G248T in parC. Thirty subjects underwent a test of cure (TOC). Azithromycin was the most common empirical regimen and moxifloxacin the main alternative.
Conclusions. High rate of resistance in our environment evidences the need for targeted therapy by genotypic study of macrolide resistance, supported by the detection of mutations in parC and gyrA to predict quinolones susceptibility and the use of TOC to evaluate treatment response

Rev Esp Quimioter 2023; 36(4): 416-420 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 408-415

Ability of qSOFA1-lactate to predict 30-day mortality in patients seen for infection in the Emergency Department

AGUSTÍN JULIÁN-JIMÉNEZ, RAFAEL RUBIO-DÍAZ, JUAN GONZÁLEZ DEL CASTILLO, ERIC JORGE GARCÍA-LAMBERECHTS, ITZIAR HUARTE SANZ, CARMEN NAVARRO BUSTOS, FRANCISCO JAVIER CANDEL, PEDRO ÁNGEL DE SANTOS, RAÚL ALONSO AVILÉS EN NOMBRE DEL GRUPO INFURG-SEMES

Published: 8 May 2023

http://www.doi.org/10.37201/req/008.2023

Objectives. To evaluate lactate and the Quick Sepsis-Related Organ Failure Assessment (qSOFA) and compare their ability to predict 30-day mortality in patients treated for infection in emergency departments (ED).
Methods. Prospective multicenter observational cohort study. We enrolled a convenience sample of patients aged 18 years or older attended in 71 Spanish ED from October 1, 2019, to March 31, 2020. Each model’s predictive power was analyzed with the area under the receiver operating characteristic curve (AUC), and its values of sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative (NPV).
Results. A total of 4439 patients with a mean (SD) age of 18 years were studied; 2648 (59.7%) were men and 459 (10.3%) died within 30 days. For 30-day mortality, the AUC-COR obtained with the qSOFA = 1 model plus 2 mmol/l lactate was 0.66 (95% CI, 0.63-0.69) with Se: 68%, Es: 70% and NPV:92%, while qSOFA = 1 obtained AUC-COR of 0.52 (95% CI, 0.49-0.55) with a Se:42%, Es:64% and NPV:90%.
Conclusions. To predict 30-day mortality in patients presenting to the ED due to an episode of infection, the qSOFA =1 + lactate≥2 mmol/L model significantly improves the predictive power achieved individually by qSOFA1 and becomes very similar to qSOFA≥2.

Rev Esp Quimioter 2023; 36(4): 408-415 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 442-443

Diagnóstico vírico alternativo en las sospechas de viruela del mono      

JORDI REINA, ELISA GONZÁLEZ DE HERRERO

Published: 4 May 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/003.2023

Rev Esp Quimioter 2023; 36(4): 442-443 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 429-431

Kikuchi-Fujimoto Disease: a rare type of lymphadenopathy and its plausible relationship with human papillomavirus vaccines     

ADRIÁN RODRÍGUEZ-FERRERAS, IVAN MARAY, COVADONGA COYA-FERNÁNDEZ, MANUELA MARÍA OCTAVIO-BOCIGAS, MANUEL FELICÍSIMO FERNÁNDEZ-DEL RÍO, SUSANA CASARES-LÓPEZ, JESÚS RUIZ-SALAZAR

Published: 3 May 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/140.2022

Rev Esp Quimioter 2023; 36(4): 429-431  [Full-text PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 427-428

Concordancia entre el GeneXpert y el Life Real Detection Kit en el diagnóstico de las infecciones respiratorias agudas     

CELIA GARCÍA-RIVERA, ISABEL ESCRIBANO, ESPERANZA MERINO, JUAN CARLOS RODRIGUEZ

Published: 3 May 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/136.2022

Rev Esp Quimioter 2023; 36(4): 427-428  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 392-399

Management of COVID-19 pandemic in hospital at home in two regional Spanish hospitals. what it meant, who we cared for, who died and how assistance has evolved over time

DAVID SÁNCHEZ FABRA, TINA HERRERO JORDÁN, ALICIA ALDA LOZANO, VICTORIA DURO SUÁREZ, NURIA SAURA BLASCO, ISABEL TORRES COURCHOUD

Published: 3 May 2023

http://www.doi.org/10.37201/req/138.2022

Introduction. Home Hospitalization (HH) is an alternative hospitalization modality that can be very useful in times of health stress such as the COVID-19 pandemic. This paper includes the management of patients admitted with COVID-19 in HH in two county spanish hospitals for two years.
Methods. A descriptive, observational and retrospective study of all patients admitted at HH with a diagnosis of COVID-19 disease was carried out. Subsequently, further analysis was carried out to characterize the patients who died in HH or 30 days after discharge and another to compare the management between the first phase of the study (2020) and the second one (2021 and part of 2022).
Results. A total of 167 patients were recruited. A 52.1% moved to watch that the recovery continued compared to 40.7% in which it was done to watch that they did not worsen. The patients who died in HAD were older (mean 87.5 years), more comorbid and more likely to have do-not resucitate orders (DNR) in case of cardiac arrest (85%). In the second phase of the study, older patients, more comorbid patients and with a greater degree of DNR orders were admitted than those admitted throughout 2020.
Conclusions. HAD is a useful resource to increase the resilience of health systems in cases of stress such as the disease caused by COVID-19. The development and growth of existing units, as well as the creation of new ones where they do not exist, could be a basic tool for the medicine of the future.

Rev Esp Quimioter 2023; 36(4): 392-399 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 400-407

Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)

CARLOS RISCO-RISCO, DIEGO MARTÍNEZ-URBISTONDO, RAFAEL SUÁREZ DEL VILLAR, LUIS AYERBE GARCÍA-MONZÓN, ALBERTO PÉREZ-RUBIO, JOSÉ BARBERÁN-LÓPEZ, DAVID ANDALUZ-OJEDA, PAULA VILLARES FERNÁNDEZ

Published: 29 April 2023

http://www.doi.org/10.37201/req/017.2023

Introduction. Comirnaty® is an mRNA vaccine against COVID-19 which has been administered to millions of people since the end of 2020. Our aim was to study epidemiological and clinical factors influencing reactogenicity and functional limitation after the first two doses of the vaccine in health care workers (HCWs).
Material and methods. Prospective post-authorization cohort study to monitor safety and effectiveness of the vaccine.
Results. Local side effects were mild and presented both with first and second dose of Comirnaty. Systemic side effects were more frequent after 2nd dose. Nevertheless, previous SARS-CoV-2 infection was associated with systemic effects after the first dose of the vaccine (OR ranging from 2 to 6). No severe adverse effects were reported. According to multivariate analysis, the degree of self-reported functional limitation after the first dose increased with age, female sex, previous COVID-19 contact, previous SARS-CoV-2 infection, and Charlson Comorbidity Index (CCI). After the second dose, the degree of functional limitation observed was lower in those with previous SARS-CoV-2 infection, and it was positively associated to the degree of functional limitation after the first dose.
Conclusion. Systemic adverse effects were more frequent after the second dose of Comirnaty. Previous SARS-CoV-2 infection was associated with systemic effects after the first dose. Age, female sex, previous COVID-19, previous isolation due to COVID-19 contact, and CCI showed to be independent predictors of the degree of functional limitation after the 1st dose of Comirnaty®. After the 2nd dose, the degree of functional limitation was lower in those who previously had SARS-CoV-2 infection.

Rev Esp Quimioter 2023; 36(4): 400-407 [Full-text PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 436-438

Ajuste posológico de linezolid por interacción con rifampicina en endocarditis infecciosa     

AARON PUPLÀ BARTOLL, Mª DOLORES BELLÉS MEDALL, IGNACIO PÉREZ CATALÁN, CELIA ROIG MARTÍ, JULIA BODEGA AZUARA, MAYTE GIL CANDEL, VICENT ESTEVE LÓPEZ, RAÚL FERRANDO PIQUERES

Published: 28 April 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/147.2022

Rev Esp Quimioter 2023; 36(4): 436-438  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 421-424

Pulmonary nocardiosis after covid-19 infection: case report and literature review    

JOSÉ ORTIZ, FRANCISCO JOVER, VICTORIA ORTIZ DE LA TABLA, ELISABET DELGADO

Published: 27 April 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/132.2022

Rev Esp Quimioter 2023; 36(4): 421-424 [Full-text PDF]


/por
,

Rev Esp Quimioter 2023; 36(4): 380-391

Reduction in the risk of progression of solid organ transplant recipients infected by SARS-CoV-2 treated with monoclonal antibodies

FRANCISCO JAVIER CANDEL, MIGUEL SALAVERT, DAVID LORITE MINGOT, MARTA MANZANO CRESPO, PAULA PÉREZ PORTERO, RAFAEL CUERVO PINTO

Published: 24 April 2023

http://www.doi.org/10.37201/req/023.2023

Recipients of solid organ transplants (SOT) are at higher risk of infection by SARS-CoV-2 virus especially due to chronic immunosuppression therapy and frequent multiple comorbid conditions. COVID-19 is a potentially life-threatening disease in SOT recipients, with an increased likelihood of progressing to severe disease, with the need of hospitalization, admission to the intensive care unit (ICU) and mechanical ventilatory support. This article presents an updated review of different aspects related to the outcome of COVID-19 in SOT recipients. In nvaccinated SOT recipients, COVID-19 is associated with a high mortality rate, in-patient care and ICU admission, and impaired graft function or rejection in severe disease. In vaccinated SOT recipients even after full vaccination, there is a reduction of the risk of mortality, but the course of COVID-19 may continue to be severe, influenced by the time from transplant, the net state of immunosuppression and having suffered graft rejection or dysfunction. SOT recipients develop lower immunity from mRNA vaccines with suboptimal response. Treatment with mAbs provides favorable outcomes in non-hospitalized SOT recipients at high risk for severe disease, with lower rates of hospitalization, emergency department visits, ICU care, progression to severe disease, and death. However, broad vaccination and therapeutic options are required, particularly in light of the tendency of the SARS-CoV-2 virus to adapt and evade both natural and vaccine-induced immunity.

Rev Esp Quimioter 2023; 36(4): 380-391 [Full-text PDF]

GRAPHICAL ABSTRACT

Download Hi-res image

 


/por